Feed Top Reports Pricing

⌘K

17:19:19·38d

SECFiling

SEC Form 10-K filed by Agenus Inc.

AGEN· Agenus Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

AGEN
Agenus Inc.
Health Care

Recent analyst ratings

Jun 4UpdateH.C. Wainwright$25.00
Jul 19UpdateRobert W. Baird$8.00
Jul 18UpdateWilliam Blair-
Jul 18UpdateH.C. Wainwright$9.00
Jun 6UpdateRobert W. Baird$8.00
Jun 6UpdateRobert W. Baird$80.00

Related

INSIDER2d
SEC Form 4 filed by Armen Garo H
PR2d
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
PR2d
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
SEC3d
SEC Form PRE 14A filed by Agenus Inc.
PR6d
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
INSIDER10d
SEC Form 4 filed by Harrison Thomas L
INSIDER17d
SEC Form 4 filed by Armen Garo H
PR20d
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022